PMID- 40983035
OWN - NLM
STAT- Publisher
LR  - 20250922
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
DP  - 2025 Sep 22
TI  - Target antigen and plasma cell phenotype are critical factors for sensitivity to 
      response-adapted daratumumab therapy.
LID - blood.2025029921 [pii]
LID - 10.1182/blood.2025029921 [doi]
AB  - In this response-adapted clinic trial with daratumumab monotherapy for elderly 
      newly diagnosed multiple myeloma (MM), we identified target antigen expression, a 
      plasma cell phenotype, and an activated immune microenvironment (iTME) as 
      critical features associated with response to CD38 monoclonal antibody therapy. 
      Here, patients achieving a partial response (PR) after 2 cycles continued 
      daratumumab, otherwise lenalidomide or bortezomib was added. This strategy 
      resulted in an overall response rate of 97% and low rates of adverse events, with 
      37% of patients able to continue daratumumab monotherapy. Importantly, we found 
      that higher CD38 expression, plasma cell gene expression programming, and an 
      activated iTME were associated with patients who were able to continue 
      daratumumab therapy alone. In contrast, patients requiring the addition of 
      lenalidomide or bortezomib had increased expression of adhesion, TNF signaling, 
      KRAS signaling, and B cell programs as well as an immunosuppressed iTME. Tracking 
      of clonal dynamics illustrated the selection of subclones enriched for de novo 
      resistance gene expression programs after only two cycles of daratumumab 
      monotherapy. Upon relapse, daratumumab refractory MM cells were characterized by 
      the expansion of pre-existing minor subclones with mixed transcriptomic programs 
      containing the plasma cell phenotype with decreased CD38 and maintenance of 
      resistance programs, suggesting development of acquired resistance involves an 
      uncoupling of transcriptional programs present in therapy naïve tumors. To our 
      knowledge, this is the first study to demonstrate the effectiveness of 
      response-adapted daratumumab treatment and describe critical biomarkers of 
      single-agent daratumumab sensitivity in vulnerable, therapy naïve MM patients. 
      NCT04151667.
CI  - Copyright © 2025 American Society of Hematology.
FAU - Meads, Mark B
AU  - Meads MB
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Zhao, Xiaohong
AU  - Zhao X
AD  - H Lee Moffitt Cancer Center & Institute, Tampa, Florida, United States.
FAU - Noyes, David R
AU  - Noyes DR
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Sudalagunta, Praneeth
AU  - Sudalagunta P
AUID- ORCID: 0000-0003-1283-9332
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Achille, Alexandra
AU  - Achille A
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Zhang, Chaomei
AU  - Zhang C
AD  - Moffitt cancer center, Tampa, Florida, United States.
FAU - Renatino Canevarolo, Rafael
AU  - Renatino Canevarolo R
AUID- ORCID: 0000-0002-8722-8512
AD  - Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Silva, Maria
AU  - Silva M
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Magaletti, Dario
AU  - Magaletti D
AD  - H Lee Moffitt Cancer Center & Institute, Tampa, Florida, United States.
FAU - DeAvila, Danny
AU  - DeAvila D
AUID- ORCID: 0009-0006-5421-3425
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Toska, Sonila
AU  - Toska S
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Oates, Ashley
AU  - Oates A
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Lastorino, Daniel
AU  - Lastorino D
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Idiaquez, Dietrich Werner
AU  - Idiaquez DW
AUID- ORCID: 0009-0001-6115-3348
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Song, Jinming
AU  - Song J
AD  - H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States.
FAU - Sansil, Samer
AU  - Sansil S
AUID- ORCID: 0000-0001-8372-7149
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Yoder, Sean J
AU  - Yoder SJ
AD  - Moffitt Cancer Center and Research Institute, Tampa, Florida, United States.
FAU - Grajales-Cruz, Ariel F
AU  - Grajales-Cruz AF
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United 
      States.
FAU - Blue, Brandon J
AU  - Blue BJ
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United 
      States.
FAU - Freeman, Ciara L
AU  - Freeman CL
AUID- ORCID: 0000-0002-0662-6480
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Kim, Jongphil
AU  - Kim J
AUID- ORCID: 0000-0002-7430-2226
AD  - H.Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States.
FAU - Alsina, Melissa
AU  - Alsina M
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United 
      States.
FAU - Brayer, Jason
AU  - Brayer J
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Siqueira Silva, Ariosto
AU  - Siqueira Silva A
AD  - H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United 
      States.
FAU - Song, Xiaofei
AU  - Song X
AD  - H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Shain, Kenneth H
AU  - Shain KH
AUID- ORCID: 0000-0003-4178-8888
AD  - Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Baz, Rachid C
AU  - Baz RC
AUID- ORCID: 0000-0003-4538-4733
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United 
      States.
LA  - eng
SI  - ClinicalTrials.gov/NCT04151667
PT  - Journal Article
DEP - 20250922
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
EDAT- 2025/09/22 18:37
MHDA- 2025/09/22 18:37
CRDT- 2025/09/22 18:02
PHST- 2025/08/13 00:00 [accepted]
PHST- 2025/05/22 00:00 [received]
PHST- 2025/08/13 00:00 [revised]
PHST- 2025/09/22 18:37 [medline]
PHST- 2025/09/22 18:37 [pubmed]
PHST- 2025/09/22 18:02 [entrez]
AID - 547403 [pii]
AID - 10.1182/blood.2025029921 [doi]
PST - aheadofprint
SO  - Blood. 2025 Sep 22:blood.2025029921. doi: 10.1182/blood.2025029921.
